BioSpace News Archive

Emmes today announced that Kathleen Wolf has joined the company as vice president of clinical operations. She has two decades of leadership experience in the biopharmaceutical industry, including most recently as a senior director with AstraZeneca’s MedImmune unit.

Following Federal Policy Changes, Healthcare Specialist Vanguard Communications Presents “Patient in a Pocket” Webinar About Conducting Patient Appointments Virtually Via Common Apps

- New Data to be Presented at NCCN 2020 Annual Conference - BeyondSpring Inc.

In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics Inc. (SmartPharm) today announced a research and development collaboration to develop a next-generation, gene-encoded antibody vaccine for COVID-19. The collaboration will utilize monoclonal antibodies against SARS-CoV-2 virus discovered and/or generated by Sorrento that will be encod

World’s only FDA-cleared six-lead personal ECG will be used by healthcare professionals to monitor QT duration in patients receiving medications that can cause potentially life threatening QT prolongation.

Genentech announced today the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial i

NEXVOO®, a global innovation leader in unified communications products, announces that it is assisting with the US and global pandemic by shifting resources to help with shipping FDA Certified N95 mask supplies into the US.

Treatment targeted for patients who are at highest risk of dying from COVID-19 due to tissue damage from infection to the lungs

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2 pandemic on its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed producer under Canada’s Cannabis Act and Regulations, and its facility in Cobourg, Ontario.

Fortress Biotech, Inc. today announced that its Board of Directors authorized the repurchase of up to $5 million of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the “Pre